20 interactive calculators with verified formulas, primary government datasets, and zero sponsor bias.
The American Cancer Society (ACS) estimates that there will be 333,830 new cases of prostate cancer in 2026, with 36,320 deaths from the disease.

The American Cancer Society (ACS) estimates that there will be 333,830 new cases of prostate cancer in 2026, with 36,320 deaths from the disease. According to editorial research analyzed by Groundwork, The number of prostate cancer cases in the United States is on the rise, according to the ACS. The ACS estimates that there will be 333,830 new cases of prostate cancer in 2026, with 36,320 deaths from the disease.
Prostate cancer cases increased by around 3% per year between 2014 and 2022, with the steepest increase occurring in advanced-stage diagnoses. The ACS says the increase in diagnoses is largely due to more men being screened, although many are still not being screened early enough.
The ACS also reported in the Cancer Statistics 2026 report that cases of prostate cancer increased by 3% each year between 2014 and 2022. The steepest increase occurred in advanced-stage diagnoses.
Additionally, the ACS noted that the increase in diagnoses is largely due to more men being screened for the disease. “We’re seeing two things happen at once: more men are being diagnosed with prostate cancer, and a growing share of those cases are happening at a more advanced stage,” William Dahut, MD, chief scientific officer at the ACS, said in a statement. “That tells us screening conversations are happening too late for too many men, particularly those at high risk for the disease.”
Prostate cancer screening can help detect the disease at an earlier stage. This September, which is Prostate Cancer Awareness Month, the ACS is encouraging males to speak with their healthcare professional about their personal risk factors and whether screening is right for them.
The ACS states that 1 in 8 men will be diagnosed with prostate cancer in their lifetime. However, most men diagnosed with prostate cancer do not die from the disease. In fact, more than 3.5 million men with prostate cancer are still alive today.
The main benefit of prostate cancer screening is early detection. When prostate cancer is found at an earlier stage, it is generally easier to treat and has a much higher survival rate. “The benefits of detecting prostate cancer at an earlier, localized stage are profound,” S. Adam Ramin, MD, board certified urologist, urologic oncologist, and medical director of Urology Cancer Specialists in Los Angeles, CA, told Healthline.
He added that when prostate cancer is found early, the result can include:
Early detection of prostate cancer can also lead to better quality of life for men diagnosed with the disease. “When we detect prostate cancer early, we can often avoid more aggressive treatments and preserve fertility, which is especially important for younger men,” Dr. Ramin said.
However, it is essential to note that not all men need to be screened for prostate cancer. The ACS recommends that men discuss their individual risk factors and whether screening is right for them with their healthcare professional. Men with a family history of prostate cancer, men of African descent, and men with a history of prostate issues should discuss their risk factors with their healthcare professional.
in summary, prostate cancer cases are rising, and early detection may help. The ACS estimates that there will be 333,830 new cases of prostate cancer in 2026, with 36,320 deaths from the disease. Prostate cancer screening can help detect the disease at an earlier stage, and early detection can lead to better treatment options and higher cure rates.
Therefore, it is essential for men to speak with their healthcare professional about their personal risk factors and whether screening is right for them. By doing so, men can take the first step towards early detection and potentially improve their chances of successful treatment and long-term cure.
Ultimately, prostate cancer screening is a essential step in the prevention and treatment of prostate cancer. By understanding the risks and benefits of screening and discussing individual risk factors with a healthcare professional, men can take control of their health and potentially save their lives.
Takeaway: Early detection of prostate cancer can lead to better treatment options, higher cure rates, and improved quality of life for men diagnosed with the disease. Men should discuss their individual risk factors and whether screening is right for them with their healthcare professional.
Expert Comment: “Prostate cancer screening is a essential step in the prevention and treatment of prostate cancer. By understanding the risks and benefits of screening and discussing individual risk factors with a healthcare professional, men can take control of their health and potentially save their lives.” Dr. S. Adam Ramin, MD, board certified urologist, urologic oncologist, and medical director of Urology Cancer Specialists in Los Angeles, CA.
FAQ:
Q: What is the recommended screening schedule for prostate cancer? A: The recommended screening schedule for prostate cancer varies depending on individual risk factors and age. Men should discuss their individual risk factors and whether screening is right for them with their healthcare professional.
Q: What are the benefits of early detection of prostate cancer? A: Early detection of prostate cancer can lead to better treatment options, higher cure rates, and improved quality of life for men diagnosed with the disease.
Q: How can men reduce their risk of developing prostate cancer? A: Men can reduce their risk of developing prostate cancer by maintaining a healthy diet, exercising regularly, and avoiding smoking and excessive alcohol consumption.
Q: What is the recommended test for prostate cancer screening? A: The recommended test for prostate cancer screening is the prostate-specific antigen (PSA) test.
Related Queries:
Translational medical literature metrics help map therapeutic breakthroughs in benign prostatic hyperplasia research citation trends.

Early breast cancer detection saved Katherine LaNasa's life. Learn how to prioritize your health and reduce your risk of developing breast cancer.
Early detection of ovarian cancer remains a clinical challenge because available blood biomarkers lack the sensitivity and specificity required for population
Altered EEG patterns co-vary with specific improvements in mind health at summer camp, suggesting that exposure to device-free natural environments supports
Contextual evidence and verified documentation referenced in this research guide
Groundwork enforces a strict, independent verification standard. All claims and benchmark figures in this guide are cross-referenced against the primary documentation and regulatory registries listed below:
Maya Okafor (2026). Prostate Cancer Cases Rising 3% Yearly, Early Detection May Help. Groundwork. Retrieved from https://gworky.com/article/prostate-cancer-cases-rising-early-detection-may-help
Originally published at https://gworky.com/article/prostate-cancer-cases-rising-early-detection-may-help — Groundwork Evidence-Based Research.
Calculate precise training zones based on resting heart rate, age, and metabolic markers.
Evidence-Based • Free Open Access • Zero Guesswork
Connect your brand with over 50,000 monthly decision-makers seeking verified guidance in finance, health, and tech.
Calculate personalized cardiovascular training zones based on age and resting metrics.
bodyEarly Breast Cancer Detection Saved Katherine LaNasa's Life: A Cautionary Tale
AI Detects a Distributed Blood Metabolomic Systemotype
Altered EEG Patterns Co-Vary with Specific Improvements in Mind Health at Summer Camp
Epigenetic Signatures of Biological Vulnerability and Residual Risk in Heart Failure
Evaluated for performance, privacy protocols, and pricing transparency.
| Solution | Key Benchmark | Pricing | Verdict & Access |
|---|---|---|---|
Check My Body HealthEditor Pick via Check My Body Health | Clinical food sensitivity & biomarker panels | $38 Test Kit | |
AG1 Protocol via Athletic Greens | NSF Certified daily micronutrient complex | $79/mo | |
Clinical Fasting Guide via Metabolic Research Lab | PubMed-backed metabolic autophagy protocol | $37 One-Time |
Health & Tech Writer
Maya Okafor is a Senior Clinical Sciences Analyst focusing on evidence-based dietary interventions, metabolic longevity markers, and pharmaceutical compounding compliance. Her research bridges molecular biology and applied lifestyle medicine, auditing commercial dietary supplements and evaluating peer-reviewed evidence to help readers distinguish scientifically validated regimens from marketing wellness hype.
Health Data Analyst
Sarah Lin heads clinical analysis for the Body & Health Sciences Desk at Groundwork. She directs primary meta-analyses of peer-reviewed randomized controlled trials (RCTs) indexed in PubMed, evaluating metabolic health, cardiovascular biomarkers, and preventative nutrition protocols. Lin ensures Groundwork's health calculators and wellness guides strictly conform to clinical evidence standards and public health guidelines.
This guide underwent secondary data verification to confirm primary source integrity, calculation formulas, and regulatory compliance before publication.